GlassScriptPhysician profile
Joshua Scott Grant
NPI 1447485461
$15,559.31
in general payments reported to CMS, 2019-2025
20 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $144 · 2021: $1,159 · 2022: $1,192 · 2023: $6,579 · 2024: $5,684 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,133 · Travel and Lodging: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,641.60 |
| Food and Beverage | $2,132.60 |
| Travel and Lodging | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12,074.46 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $1,720.03 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $574.94 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $277.90 | 2022-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $125.82 | 2022-2025 | Miebo, Xiidra, Xipere |
| Astellas Pharma US INC | $108.86 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $104.09 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.54 | 2019-2021 | |
| Harrow Eye, LLC | $82.57 | 2025 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $75.06 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $50.02 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $46.11 | 2019-2023 | Tecnis Iol |
| Abbvie INC. | $44.30 | 2023-2024 | |
| Alcon Vision LLC | $42.33 | 2023-2025 | Argos, Precision 1 |
| Allergan, INC. | $32.24 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.23 | 2019 | |
| Boston Scientific Corporation | $19.93 | 2024 | |
| Coherus Oncology, INC. | $19.13 | 2023 | |
| Merz Pharmaceuticals, LLC | $17.58 | 2022 | |
| Oyster Point Pharma, INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.